Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07448831 | A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.(NeoSenti) | recruiting | Phase 2 | 49 | Universitair Ziekenhuis BrusselOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07449754 | Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | recruiting | Phase 2 | 45 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Mar 4, 2026 |
| clinicaltrials |
| NCT04091750 | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | active not recruiting | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT04093323 | Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03400332 | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | completed | Phase 1 / Phase 2 | 281 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 24, 2026 | clinicaltrials |
| NCT06627244 | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | recruiting | Phase 2 | 30 | University of MiamiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT01659151 | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04971499 | A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma | active not recruiting | Phase 1 / Phase 2 | 26 | April Salama, M.D.OTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06999980 | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)(Neo IRENIE) | recruiting | Phase 2 | 494 | Melanoma Institute AustraliaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02517736 | Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination(O-Mel-Sora) | completed | Phase 2 | 32 | University Hospital, CaenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | active not recruiting | Phase 2 / Phase 3 | 420 | IDEAYA BiosciencesINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT07411144 | Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma(GEMO) | completed | Phase 2 | 64 | National Cancer Institute, EgyptOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07406724 | HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma | not yet recruiting | Phase 2 | 90 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT04552223 | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 27 | Jose Lutzky, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | active not recruiting | Phase 2 | 151 | Regeneron PharmaceuticalsINDUSTRY | 8 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT05418972 | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma(Neo ReNi II) | active not recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | terminated | Phase 1 / Phase 2 | 46 | SanofiINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT05419388 | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | completed | Phase 2 | 93 | Hoffmann-La RocheINDUSTRY | 10 | Feb 4, 2026 | clinicaltrials |
| NCT03340129 | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)(ABC-X) | recruiting | Phase 2 | 218 | Melanoma Institute AustraliaOTHER | 2 | Feb 2, 2026 | clinicaltrials |
| NCT03815058 | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.(IMCODE001) | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 6 | Jan 30, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03957551 | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 28 | John RiethOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04157517 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 45 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 2 | Jan 29, 2026 | clinicaltrials |
| NCT07376317 | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)(OTIMAS) | active not recruiting | Phase 2 | 29 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT00626860 | The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma | completed | Phase 1 / Phase 2 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | active not recruiting | Phase 2 | 150 | Agenus Inc.INDUSTRY | 10 | Jan 16, 2026 | clinicaltrials |
| NCT06717126 | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma(OCULE-01) | active not recruiting | Phase 2 | 85 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07336979 | Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03873818 | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | recruiting | Phase 2 | 105 | NYU Langone HealthOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04129515 | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Brown UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06120712 | A Study of GC101 TIL in Advanced Melanoma (BZ)(MIZAR-002) | completed | Phase 1 / Phase 2 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04079166 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | active not recruiting | Phase 2 | 173 | Scancell LtdINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04688658 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 13 | John KirkwoodOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT01950390 | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 169 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2026source: clinicaltrials